

<https://helda.helsinki.fi>

Risk factors for major adverse cardiovascular events after the first acute coronary syndrome

Okkonen, Marjo

2021-01-01

Okkonen , M , Havulinna , A S , Ukkola , O , Huikuri , H , Pietilä , A , Koukkunen , H , Lehto , S , Mustonen , J , Ketonen , M , Airaksinen , J , Kesäniemi , Y A & Salomaa , V 2021 , ' Risk factors for major adverse cardiovascular events after the first acute coronary syndrome ' , Annals of Medicine , vol. 53 , no. 1 , pp. 817-823 . <https://doi.org/10.1080/07853890.2021.1924395>

<http://hdl.handle.net/10138/332745>

<https://doi.org/10.1080/07853890.2021.1924395>

cc_by


publishedVersion

Downloaded from Helda, University of Helsinki institutional repository.

This is an electronic reprint of the original article.

This reprint may differ from the original in pagination and typographic detail.

Please cite the original version.



Risk factors for major adverse cardiovascular events after the first acute coronary syndrome

Marjo Okkonen, Aki S. Havulinna, Olavi Ukkola, Heikki Huikuri, Arto Pietilä, Heli Koukkunen, Seppo Lehto, Juha Mustonen, Matti Ketonen, Juhani Airaksinen, Y. Antero Kesäniemi & Veikko Salomaa

To cite this article: Marjo Okkonen, Aki S. Havulinna, Olavi Ukkola, Heikki Huikuri, Arto Pietilä, Heli Koukkunen, Seppo Lehto, Juha Mustonen, Matti Ketonen, Juhani Airaksinen, Y. Antero Kesäniemi & Veikko Salomaa (2021) Risk factors for major adverse cardiovascular events after the first acute coronary syndrome, *Annals of Medicine*, 53:1, 817-823, DOI: [10.1080/07853890.2021.1924395](https://doi.org/10.1080/07853890.2021.1924395)

To link to this article: <https://doi.org/10.1080/07853890.2021.1924395>



© 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group



Published online: 03 Jun 2021.



[Submit your article to this journal](#)



Article views: 536



[View related articles](#)



[View Crossmark data](#)

ORIGINAL ARTICLE



Risk factors for major adverse cardiovascular events after the first acute coronary syndrome

Marjo Okkonen^{a,b}, Aki S. Havulinna^{c,d} , Olavi Ukkola^{a,b} , Heikki Huikuri^{a,b}, Arto Pietilä^c, Heli Koukkunen^{e,f} , Seppo Lehto^f, Juha Mustonen^g, Matti Ketonen^g, Juhani Airaksinen^h , Y. Antero Kesäniemi^{a,b} and Veikko Salomaa^c 

^aResearch Unit of Internal Medicine, University of Oulu, Oulu, Finland; ^bMedical Research Center Oulu, Oulu University Hospital, Oulu, Finland; ^cFinnish Institute for Health and Welfare, Helsinki, Finland; ^dFIMM: Institute for Molecular Medicine Finland, Helsinki, Finland; ^eKuopio University Hospital, Kuopio, Finland; ^fUniversity of Eastern Finland, Kuopio, Finland; ^gNorth Karelia Central Hospital, Joensuu, Finland; ^hUniversity of Turku and Heart Center Turku University Hospital, Turku, Finland

ABSTRACT

Aims: To evaluate risk factors for major adverse cardiac event (MACE) after the first acute coronary syndrome (ACS) and to examine the prevalence of risk factors in post-ACS patients.

Methods: We used Finnish population-based myocardial infarction register, FINAMI, data from years 1993–2011 to identify survivors of first ACS ($n = 12686$), who were then followed up for recurrent events and all-cause mortality for three years. Finnish FINRISK risk factor surveys were used to determine the prevalence of risk factors (smoking, hyperlipidaemia, diabetes and blood pressure) in post-ACS patients ($n = 199$).

Results: Of the first ACS survivors, 48.4% had MACE within three years of their primary event, 17.0% were fatal. Diabetes ($p = 4.4 \times 10^{-7}$), heart failure (HF) during the first ACS attack hospitalization ($p = 6.8 \times 10^{-15}$), higher Charlson index ($p = 1.56 \times 10^{-19}$) and older age ($p = .026$) were associated with elevated risk for MACE in the three-year follow-up, and revascularization ($p = .0036$) was associated with reduced risk. Risk factor analyses showed that 23% of ACS survivors continued smoking and cholesterol levels were still high ($>5\text{mmol/l}$) in 24% although 86% of the patients were taking lipid lowering medication.

Conclusion: Diabetes, higher Charlson index and HF are the most important risk factors of MACE after the first ACS. Cardiovascular risk factor levels were still high among survivors of first ACS.

ARTICLE HISTORY

Received 2 November 2020
Revised 5 April 2021
Accepted 26 April 2021

KEYWORDS

Epidemiology; acute coronary syndromes; prevention; major adverse cardiac event

Introduction

Cardiovascular diseases (CVD) are the leading cause of death in many countries. In 2017 17.8 million people died because of a CVD event [1]. Many studies have been published on risk factors for coronary heart disease (CHD) which is the leading component of CVD [1,2]. Age, male sex, hypertension, hyperlipidaemia, diabetes and cigarette smoking are commonly considered as risk factors for CHD [3–6]. Also, left ventricular systolic dysfunction, severity of CHD and comorbidities are associated with high risk of an adverse outcome [3,5,7].

Different risk indicators for major adverse cardiac event (MACE) after an acute coronary syndrome (ACS), such as angiographic outcome and left ventricular function, have been previously observed [6,7]. Also, the short-term risk of MACE after ACS is well known

[5,8,9]. However, the long-term risk factors for MACE after an ACS have been rarely examined [5,8,10,11]. Previous studies have focussed on MACE after either a non-ST-elevation myocardial infarction (NSTEMI) or ST-elevation myocardial infarction (STEMI) and current studies rarely separate between MACE after the first event or recurrent event [5,7,11,12].

Major improvements have taken place in diagnosis and treatment of ACS during past decades [13]. This may have led to changes in most common risk factors for MACE after ACS. The risk factors may be different for first versus recurrent event and the risk factors for long- and short-term recurrence may differ. Therefore, it is important to evaluate the entire spectrum of MACE after ACS in a long-term study.

The purpose of our study was to evaluate risk factors for MACE within one- and three-year time periods after the first ACS event. In particular we wanted to

CONTACT Marjo Okkonen  marjoppi@student.oulu.fi  Research Unit of Internal Medicine, P.O. Box 5000, Oulu FIN- 90014, Finland

© 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

identify modifiable risk factors, which could provide treatment targets for further improvements in prognosis after the first ACS. We also examined the prevalence of risk factors (smoking, hyperlipidaemia, diabetes and blood pressure) among a population-based sample of post-ACS patients from the FINRISK risk factor survey-populations to gain understanding of the current treatment and control levels of these risk factors.

Methods

This study was based on a follow-up of the FINAMI participants. The FINAMI register has been described previously [14]. In brief, it was a population-based myocardial infarction register, which was functioning in four different geographical areas of Finland. FINAMI registered all events from Oulu, Joensuu, Turku and Kuopio areas that were or were suspected to be myocardial infarction (MI), unstable angina pectoris (UAP) or CHD death [14]. Trained nurses collected the data manually from hospital records [14]. FINAMI has received approval from the Ethics Committee of the National Institute for Health and Welfare during 21 January 2004.

Diagnostic classification of events was done according to the American Heart Association (AHA) Scientific Statement of 2003 [15] and before that according to the WHO MONICA Project criteria [16]. The duration of attack was defined as 28 days after onset of the attack. The most severe symptoms and findings during this time frame were recorded [14]. The attack was defined as the first if there was no mention of previous symptomatic events in the hospital records.

All symptomatic patients registered for their first ACS in 1993–2011 aged 35 to 74 years were included in this study. Included patients did not have any previous symptomatic events according to the hospital records and they had survived the first 28 days of their first ACS event. MACE during the follow-up was identified by record linkage of the FINAMI data based on the personal ID code with the National Hospital Discharge Register (NHDR) and the Causes of Death Register (CDR). Endpoints of the follow up (MACE) were new fatal or non-fatal ACS (UAP or MI), fatal or non-fatal heart failure (HF), fatal or non-fatal stroke, fatal or non-fatal CVD event and all-cause death. These events were identified from the NHDR and the CDR using international classification of diseases (ICD) 9 and 10 (Finnish version) codes. Please see appendices for the specific codes.

We also examined a sample of FINRISK survey [17] participants from survey years 2007 ($n = 6258$) and 2012 ($N = 5827$) to assess the prevalence of identified cardiovascular risk factors amongst those participants who had previously had ACS. FINRISK population has been described in more detail in our previous article [14]. In short, these patients were from the same geographic areas as the FINAMI patients and were aged 25–74 years. The same ICD 10 (Finnish version) codes were used to identify patients with a history of ACS event as for the FINAMI population.

Statistical methods

Examination of the data revealed that the proportional hazards assumption was not fulfilled in time to event models and therefore logistic regression was used to calculate the odds ratios and confidence intervals for risk factors of MACE. The models were adjusted for age, sex (when relevant), study area and the year of the event. Comparison of risk factors for MACE between patients with different ACS event-types was done using multivariate analysis which was adjusted for age, study area and the year of event. Charlson index [18] was used to evaluate the effect of comorbidity on mortality. It gives weighted points to patients comorbidities [18]. History of MI, HF, peripheral vascular disease, cerebrovascular disease, para- and hemiplegia, chronic obstructive lung disease, rheumatoid disease, peptic ulcer disease, mild liver disease and diabetes mellitus (DM) are weighed with one point. DM with target organ damage, dementia, renal disease and any cancer were weighted two points. Moderate to severe liver disease was weighted with three points and metastatic solid tumour and AIDS (stage C) were weighted with six points [18]. For the FINRISK population, the prevalence of current smoking, high blood cholesterol level, use of lipid lowering drugs, diabetes and hypertension were estimated.

Results

Altogether, 12,686 patients survived 28 days after their first ACS episode (Table 1). This was 61.9% of the total first ever ACS patient population. Of these patients, 34.4% had MACE within one year and 48.4% within three years of their primary event. Of these recurrent MACE events, 17.6% were fatal within three years. We also carried out a separate analysis, including only the latest study years, 2006–2011. During this period, altogether 3261 patients survived 28 days after their first ACS episode. This was 62.3% of the total first ever

Table 1. Clinical characteristics of the study population.

	Men	Women	Total
Survivors after first ACS (%*)	6676 (62.8)	6010 (60.9)	12,686 (61.9)
Death within 1 year (%)	661 (9.9)	881 (14.7)	1542 (12.2)
Death within 3 years (%)	1369 (20.5)	1783 (29.7)	3152 (24.9)
MACE within 1 year (%**)	2221 (33.3)	2143 (35.7)	4364 (34.4)
MACE within 3 years (%)	3019 (45.2)	3075 (51.2)	6094 (48.4)
Fatal MACE within 3 years (%)	852 (12.8)	1300 (21.6)	2152 (17.0)
Average age at MACE (SD)	67.5 (11.9)	76.9 (10.9)	72.0 (12.3)
Time from the first ACS to subsequent MACE in years (SD)	0.73 (0.76)	0.80 (0.78)	0.77 (0.77)
Stroke within 3 years (%)	448 (6.7)	522 (8.7)	970 (7.7)
ACS within 3 years (%)	2281 (34.2)	2092 (34.8)	4373 (34.5)
HF within first 28 days (%)	817 (12.2)	1231 (20.5)	2048 (16.4)
Prevalent DM among 28-day survivors (%)	729 (10.9)	872 (14.5)	1601 (12.6)
Current- / ex- / non-smokers among 28-day survivors (%)	1371 / 1290 / 721 (40.5 / 38.1 / 21.3)	480 / 314 / 1520 (20.7 / 13.6 / 65.7)	1851 / 1604 / 2241 (32.5 / 28.2 / 39.3)
Total cholesterol, mean (SD)	4.87 (1.18)	5.05 (1.27)	4.94 (1.22)
N (%) of cholesterol > 5mmol/l	2103 (41.7)	1608 (47.2)	3711 (43.9)

ACS: acute coronary syndrome; MACE: major adverse cardiac event; SD: standard deviation; MI: myocardial infarction; HF: heart failure; DM: diabetes mellitus.

*Percent of all first ACS cases.

** Percent of first MI survivors.

Table 2. Risk factors for MACE after the first ACS event. All the risk factors were modelled independently of other risk factors and adjusted for age, sex and event year.

	MACE at one year (n = 4364) OR (CI / p Value)	MACE at three years (n = 6094) OR (CI / p Value)
Age (per 10 years)	0.94 (0.88–1.01/.08)	1.07 (1.01–1.14/.026)
Sex (=female)	0.88 (0.77–1.02/.095)	0.93 (0.81–1.06/.28)
Event year	0.99 (0.97–1.00/.13)	0.98 (0.97–1.00/.077)
Diabetes	1.39 (1.17–1.64/1.3 × 10 ⁻⁴)	1.51 (1.29–1.77/4.4 × 10 ⁻⁷)
Cholesterol (per SD)	1.00 (0.92–1.07/.93)	0.96 (0.9–1.03/.28)
Current smoking	1.12 (0.96–1.31/.14)	1.14 (0.98–1.31/.081)
Revascularization (within 28 days)	0.84 (0.73–0.97/.021)	0.82 (0.71–0.94/.0036)
Primary HF	1.95 (1.63–2.34/1.9 × 10 ⁻¹³)	1.98 (1.67–2.36/6.8 × 10 ⁻¹⁵)
Primary AF	1.1 (0.91–1.33/.33)	1.11 (0.93–1.33/.25)
Use of thrombolytic treatment	1.12 (0.94–1.32/.2)	1.18 (1.01–1.38/.035)
Charlson index* per 1 point	1.11 (1.09–1.13/1.94 × 10 ⁻²¹)	1.09 (1.07–1.12/1.56 × 10 ⁻¹⁹)
UAP (as AHADG, 15.4% of all cases)	0.99 (0.83–1.17/.089)	1.11 (0.95–1.3/.18)

MACE: major adverse cardiac event; ACS: acute coronary event; OR: odds ratio; CI: confidence interval; SD: standard deviation; HF: heart failure; AF: atrial fibrillation.

*Calculated in separate model, because the Charlson index includes primary HF and AF, adjusted for age and sex. The other ORs were produced in the same model.

ACS patient population. Of these patients, 36.2% had MACE within one year and 48.4% within three years of their primary event. Of these recurrent MACE events, 15.5% were fatal within three years. Among the whole study population, the average age of having MACE after the first ACS was 67.5 years for men and 76.9 for women. The average time from ACS to MACE was less than one year (0.77 years).

DM and HF within the first 28 days of first ACS attack and higher Charlson index were associated with higher risk of MACE at one-year follow-up (Table 2). In the three-year follow-up higher age and the same risk factors: DM, HF and Charlson index were associated with higher risk of MACE. Only revascularization was a protective factor in both one- and the three-year follow-up.

Age, DM, and Charlson index were associated with higher risk of stroke both in one- and three-year follow-up (Table 3). Female sex and revascularization were protective from stroke at one-year time point. At

three-year follow-up higher blood cholesterol was inversely associated with stroke risk.

Table 4 shows risk factors for fatal MACE within three years of index event (n = 2152). Older age, diabetes and primary HF increased the risk of fatal MACE and protective factors were revascularization and later year of the event.

The prevalence of risk factors among FINRISK participants (from survey-years 2007 and 2012) who had a history of their first ACS (N = 199) is shown in Table 5. After the ACS event, 23% of patients were still smoking. The number of patients currently taking lipid lowering drugs after ACS event was high (86%) but still 24% of them had total cholesterol 5 mmol/l or more.

Discussion

The risk of recurrent MACE was high among survivors of first ever ACS and a substantial proportion of these

Table 3. Risk factors for stroke after the first ACS event. All the risk factors were modelled independently of other risk factors and adjusted for age, sex and event year.

	Stroke at one year (<i>n</i> = 545 (men = 250 and women = 295)) OR (CI / <i>p</i> Value)	Stroke at three years (<i>n</i> = 970 (men = 448 and women = 522)) OR (CI / <i>p</i> Value)
Age (per 10 years)	1.37 (1.14–1.65 / 9.3×10^{-4})	1.41 (1.23–1.63/ 1.4×10^{-6})
Sex (=female)	0.66 (0.45–0.97/.033)	0.79 (0.59–1.05/.10)
Event year	1.00 (0.95–1.06/.85)	0.98 (0.94 – 1.01/.22)
Diabetes mellitus	1.84 (1.24–2.72/ .0022)	1.82 (1.35–2.43/ 6.6×10^{-5})
Cholesterol (per SD)	0.9 (0.73–1.1/.31)	0.82 (0.7–0.96/.014)
Current Smoking	0.96 (0.63–1.48/.87)	0.92 (0.67–1.28/.64)
Revascularization (within 28 days)	0.63 (0.42–0.93/ .021)	0.83 (0.62–1.12/.22)
Primary HF	0.69 (0.42–1.12/ .13)	0.8 (0.56–1.13/.21)
Primary AF	0.97 (0.6–1.57/.92)	0.98 (0.69–1.39/.9)
Use of thrombolytic treatment	0.82 (0.49–1.37 /.44)	1.06 (0.75–1.50 /.74)
Charlson index* per 1 point	1.22 (1.10–1.36/ 2.9×10^{-4})	1.14 (1.05–1.25 / .0026)
UAP as index event (15.4% of all cases)	1.18 (0.76–1.84/.45)	0.95 (0.67–1.35 / .78)

ACS: acute coronary event; OR: odds ratio; CI: confidence interval; SD: standard deviation; HF: heart failure; AF: atrial fibrillation.

*Calculated in separate model, because the Charlson index includes primary HF and AF, adjusted for age and sex. The other ORs were produced in the same model.

Table 4. Risk factors for fatal MACE (*n* = 2152) within three years of index event.

	OR	CI	<i>p</i> Value
Event Year	0.92	(0.9–0.95)	7.9e-8
Sex (female)	0.83	(0.68–1)	.053
Age per 10 years	1.53	(1.39–1.7)	4.6e-17
Diabetes	2.38	(1.94–2.91)	7.3e-17
Cholesterol > 5 vs. ≤5	0.95	(0.86–1.05)	.3
Current smoking	1.13	(0.9–1.42)	.28
Revascularization (within 28 days)	0.56	(0.45–0.7)	1.5e-7
Primary HF	2.46	(1.99–3.02)	3e-17
Primary AF	1.02	(0.81–1.28)	.89
UAP as index event (15.4% of all cases)	1.04	(0.82–1.32)	.75

MACE: major adverse cardiac event; OR: odds ratio; CI: confidence interval; HF: heart failure; AF: atrial fibrillation; UAP: unstable angina pectoris.

Table 5. Prevalence of known risk factors among FINRISK 2007 and 2012 survey participants with a history of first ACS event.

Variable	Men	Women	Total
<i>N</i>	158 (100%)	41 (100%)	199 (100%)
Smoking	34 (21%)	11 (27%)	45 (23%)
Cholesterol (>5mmol/l)	27 (17%)	21 (54%)	48 (24%)
Lipid lowering drug use	144 (91%)	27 (66%)	171 (86%)
Diabetes mellitus	57 (36%)	16 (39%)	73 (37%)
Hypertension (Bp >140/90 or on medication)	114 (74%)	29 (74%)	143 (74%)

ACS: acute coronary syndrome; BP: blood pressure.

events was fatal. Of first ever ACS patients 34.4% had MACE within one year and 48.4% within three years of their primary event. Previous studies have shown that 20.4% to 36.7% patients have MACE after ACS. The proportion is lower for patient who have had revascularization during the first attack [12,19]. DM and HF during the first attack and high Charlson comorbidity index were associated with a higher risk for MACE within one- and three- years after the first ACS event. Higher age was associated with higher risk in the three-year follow-up. A revascularization procedure was the only protective factor in both one- and three-year time points. In FINRISK population, the risk factors

were still sub-optimally controlled amongst patients who had survived one ACS event.

Not surprisingly, the higher Charlson comorbidity index was associated with a higher risk for MACE and stroke within one and three years after the first ACS event in our study. It is likely that this is mainly due to DM and HF being part of Charlson index. However, other risk factors may also play a role since a previous study by Radovanovic et al. [20] shows higher prevalence of elevated blood cholesterol, hypertension and obesity in people with higher Charlson index.

Major improvements have taken place in the diagnosis and treatment of ACS during our study period [13,14]. In our study population from the years 1993–2011, only one in four had angiographies during the first attack. Revascularization became better available in Finland only after the year 2000 and has now reached a plateau [21]. Even though the number of patients who had angiography during first attack period was relatively small in our study, revascularization was still protective factor. This is in line with previous studies [5,19,22]. To explore the effects of improved treatments, we carried out a separate analysis for the later study years, 2006–2011. The results showed an improvement in both short- and long-term survival, but among survivors the proportion of recurrent MACE events remained the same. Because of the amount of revascularization procedures has reached a plateau [21] it is fair to assume that if we aim to improve long-term prognosis of ACS patients we should also target the modifiable risk factor.

Most important modifiable risk factors for CVD include hypertension, smoking, DM, obesity, physical inactivity, unhealthy diet, high cholesterol and other lipids and psychosocial factors [23–24]. In our study, cholesterol was not a statistically significant risk factor for MACE after ACS, which may be due to widespread

use of statins after the first ACS event. In our FINRISK population 86% of patients were taking lipid lowering medication. However, 24% of the patients still had total cholesterol 5 mmol/l or more even with lipid lowering medication.

Smoking at the time of the first ACS tended to be associated with elevated risk of future MACE but did not reach statistical significance probably because many patients stop smoking after the first ACS. However, in our FINRISK sample 23% of patients were still smoking after their first ACS. The FINRISK population showed suboptimal secondary prevention after the first ACS. Our sample size of post-ACS patients is smallish, but the findings are consistent with the EUROASPIRE study [25].

A previous study by our group [26] showed that regular use of secondary preventive medications lowers the risk of recurrent ACS after the primary attack and that the use of medications was suboptimal in the elderly and in patients with diabetes. In our present study the elderly and patients with DM were both at higher risk of MACE after ACS and the suboptimal use of medication, and thus suboptimal secondary prevention, could in part explain the high MACE rate for these patients. The specific medication data was not available for our study and we did not have the blood pressure values either.

The strength of our study is the FINAMI register which was a large, population-based register covering all ACS cases in monitored populations. FINAMI data enabled us to identify and analyse all first ACS events in populations of the register areas, and the record linkage of FINAMI data to the NHDR and the CDR through the personal ID number made it possible to identify patients who had MACE after the first ACS event. This ensured complete identification of the MACE patients who were hospitalized or who died either in hospital or out of hospital.

In addition to the previously mentioned limitations, FINAMI does not separate NSTEMI from STEMI. Therefore, we could not consider different types of MI. While NHDR diagnosis for MI has shown to be valid [27] this is not the case for the NSTEMI and STEMI diagnoses [28].

In conclusion, DM and HF are the most important risk factors for MACE after ACS. Revascularization was clearly protective factor. Also, the treatment of risk factors seems to be at suboptimal level among the survivors of first ACS. Based on our findings in FINRISK population, especially hypercholesterolaemia should be treated more aggressively and patients should be actively encouraged to stop smoking. This highlights

the importance of secondary prevention for ACS patients and also the significance of up-to-date scientific research on risk factors and their changes in populations.

Author contributions

MO: contributed to conception, design and interpretation. Drafted the manuscript.

ASH: contributed to conception, design, data acquisition, data analysis and interpretation. Critically revised the manuscript.

VS and OU: contributed to conception, design, data acquisition and interpretation. Critically revised the manuscript.

HH, HK, SL, JM, MK, JA and YAK: contributed to design and data acquisition. Critically revised the manuscript.

AP: contributed to design and data analysis. Critically revised the manuscript.

Acknowledgements

The skillful and professional contribution of the FINAMI study nurses during the data collection is gratefully acknowledged.

Disclosure statement

Marjo Okkonen has ongoing research collaboration with Novo Nordisk and Orion Pharma and has received travel grant from Novartis. JA has received consulting fees from Bayer and Pfizer and has also received lecture fees from MSD, AstraZeneca, Boehringer Ingelheim and Pfizer. YAK has received research funding from MSD. VS has received travel support from Novo Nordisk and consulting fees from Novo Nordisk and Sanofi. He also has ongoing research collaboration with Bayer Ltd. The other authors declare no conflicts of interest.

Funding

FINAMI study was supported by the Finnish Foundation for Cardiovascular Research. MO has received funding from the Medical Research Centre of Oulu Doctoral Program and State Research Funding. VS has received funding from the Finnish Foundation for Cardiovascular Research.

ORCID

Aki S. Havulinna  <http://orcid.org/0000-0002-4787-8959>
 Olavi Ukkola  <http://orcid.org/0000-0001-7414-2608>
 Heli Koukkunen  <http://orcid.org/0000-0001-6650-8075>
 Juhani Airaksinen  <http://orcid.org/0000-0002-0193-568X>
 Veikko Salomaa  <http://orcid.org/0000-0001-7563-5324>

References

- [1] Mensah G, Roth G, Fuster V. The global burden of cardiovascular diseases and risk factors: 2020 and beyond. *J Am Coll Cardiol*. 2019;74(20):2529–2532.
- [2] Timmis A, Townsend N, Gale CP, et al. European society of cardiology: cardiovascular disease statistics 2019. *Eur Heart J*. 2020;41(1):12–85.
- [3] D'Agostino RB, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham heart study. *Circulation*. 2008;117(6):743–753.
- [4] Wattanakit K, Folsom AR, Chambless LE, et al. Risk factors for cardiovascular event recurrence in the atherosclerosis risk in communities (ARIC) study. *Am Heart J*. 2005;149(4):606–612.
- [5] Lansky AJ, Goto K, Cristea E, et al. Clinical and angiographic predictors of short- and long-term ischemic events in acute coronary syndromes: results from the acute catheterization and urgent intervention triage strategy (ACUITY) Trial. *Circulation*. 2010;3(4):308–316.
- [6] St John Sutton M, Pfeffer MA, Plappert T, et al. Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. The protective effects of captopril. *Circulation*. 1994;89(1):68–75.
- [7] Ng VG, Lansky AJ, Meller S, et al. The prognostic importance of left ventricular function in patients with ST-segment elevation myocardial infarction: the HORIZONS-AMI trial. *Eur Heart J Acute Cardiovasc Care*. 2014;3(1):67–77.
- [8] Lee JH, Park HS, Chae SC, et al. Predictors of six-month major adverse cardiac events in 30-day survivors after acute myocardial infarction (from the Korea acute myocardial infarction registry). *Am J Cardiol*. 2009;104(2):182–189.
- [9] Dunlay SM, Weston SA, Killian JM, et al. Thirty-day rehospitalizations after acute myocardial infarction. A cohort study. *Ann Intern Med*. 2012;157(1):11–18.
- [10] Arnold SV, Smolderen KG, Kennedy KF, et al. Risk factors for rehospitalization for acute coronary syndromes and unplanned revascularization following acute myocardial infarction. *J Am Heart Assoc*. 2015;4(2). DOI:10.1161/JAHA.114.001352.
- [11] Mueller HS, Cohen LS, Braunwald E, et al. Predictors of early morbidity and mortality after thrombolytic therapy of acute myocardial infarction. Analyses of patient subgroups in the thrombolysis in myocardial infarction (TIMI) trial, phase II. *Circulation*. 1992;85(4):1254–1264.
- [12] Tsai IT, Wang CP, Lu YC, et al. The burden of major adverse cardiac events in patients with coronary artery disease. *BMC Cardiovasc Disord*. 2017;17(1):7.
- [13] Floyd KC, Yarzebski J, Spencer FA, Lessard D, et al. A 30-year perspective (1975–2005) into the changing landscape of patients hospitalized with initial acute myocardial infarction: worcester heart attack study. *Circulation*. 2009;2(2):88–95.
- [14] Piironen M, Ukkola O, Huikuri H, et al. Trends in long-term prognosis after acute coronary syndrome. *Eur J Prev Cardiol*. 2017;24(3):274–280.
- [15] Luepker RV, Apple FS, Christenson RH, et al. Case definitions for acute coronary heart disease in epidemiology and clinical research studies: a statement from the AHA Council on Epidemiology and Prevention; AHA Statistics Committee; World Heart Federation Council on Epidemiology and Prevention; the European Society of Cardiology Working Group on Epidemiology and Prevention; Centers for Disease Control and Prevention; and the National Heart, Lung, and Blood Institute. *Circulation*. 2003;108(20):2543–2549.
- [16] MONICA Manual. Part IV. Event registration section 1: Coronary event registration data component. [Internet]; 1999 (cited 2015 Jun 23). <http://www.thl.fi/publications/monica/manual/part4/iv-1.htm>.
- [17] Borodulin K, Tolonen H, Jousilahti P, et al. Cohort profile: the National FINRISK study. *Int J Epidemiol*. 2018;47(3):696–696i.
- [18] Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis*. 1987;40(5):373–383.
- [19] Stone GW, Maehara A, Lansky AJ, et al. A prospective natural-history study of coronary atherosclerosis. *N Engl J Med*. 2011;364(3):226–235.
- [20] Radovanovic D, Seifert B, Urban P, et al. Validity of Charlson comorbidity index in patients hospitalised with acute coronary syndrome. Insights from the nationwide AMIS Plus registry 2002–2012. *Heart*. 2014;100(4):288–294.
- [21] Kiviniemi TO, Pietilä A, Gunn JM, et al. Trends in rates, patient selection and prognosis of coronary revascularization in Finland between 1994 and 2013: the CVDR. *EuroIntervention*. 2016; 12(9):1117–1125.
- [22] Briffa T, Hickling S, Knuiman M, et al. Long term survival after evidence based treatment of acute myocardial infarction and revascularisation: follow-up of population based Perth MONICA cohort, 1984–2005. *BMJ*. 2009;338:b36.
- [23] Balakumar P, Maung-U K, Jagadeesh G. Prevalence and prevention of cardiovascular disease and diabetes mellitus. *Pharmacol Res*. 2016;113(Pt A):600–609.
- [24] Yusuf PS, Hawken S, Öunpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study. *Lancet*. 2004;364(9438):937–952.
- [25] Kotseva K, De Backer G, De Bacquer D, et al. Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry. *Eur J Prev Cardiol*. 2019;26(8):824–835.
- [26] Salomaa V, Paakkonen R, Hamalainen H, et al. Use of secondary preventive medications after the first attack of acute coronary syndrome. *Eur J Cardiovasc Prev Rehabil*. 2007;14(3):386–391.
- [27] Mahonen M, Salomaa V, Brommels M, et al. The validity of hospital discharge register data on coronary heart disease in Finland. *Eur J Epidemiol*. 1997;13(4):403–415.
- [28] Okkonen M, Havulinna AS, Ukkola O, et al. The validity of hospital discharge register data on non-ST-elevation and ST-elevation myocardial infarction in Finland. *Scand Cardiovasc J*. 2020; 54(2):108–114.

APPENDIX

ICD codes

International Classification of Diseases (ICD) codes were used to cross-check the FINAMI data with the National Hospital Discharge Register (NHDR) and the Causes of Death Register (CDR). ICD 9 (Finnish version) was used until the end of 1995 and ICD 10 (Finnish version) after that. Out of hospital deaths were evaluated if the underlying or direct cause of death was coronary heart disease (ICD 9: 410–414, ICD 10: I20–I25) or cardiac arrest (I46.1, I46.9). Sudden death was also considered for registration if the cause was unknown or unattended death (ICD 9: 798, ICD 10: R96, R98). The National Hospital Discharge register was cross-checked for hospitalisation due to MI or UAP (ICD 9: 410–411, ICD 10: I20–22). The local registration teams evaluated these cases according to the registration protocol [1,2]. NHDR and CDR have been validated earlier [3]. Stroke was identified using ICD 9 codes 431, 4330 A, 4331 A, 4339 A, 4340 A, 4341 A, 4349 A and 436, and ICD 10 codes I61, I63 and I64 (except I63.6 was excluded) from the NHDR and the CDR. Heart failure was identified using ICD 9 codes 428 and 4289X, and ICD 10 codes I50 and I50.0 from the NHDR and CDR.

Funding

FINAMI study was supported by the Finnish Foundation for Cardiovascular Research. MO has received funding from the Medical Research Centre of Oulu Doctoral Program and

State Research Funding. VS has received funding from the Finnish Foundation for Cardiovascular Research.

ORCID

Aki S. Havulinna  <http://orcid.org/0000-0002-4787-8959>
 Olavi Ukkola  <http://orcid.org/0000-0001-7414-2608>
 Heli Koukkunen  <http://orcid.org/0000-0001-6650-8075>
 Juhani Airaksinen  <http://orcid.org/0000-0002-0193-568X>
 Veikko Salomaa  <http://orcid.org/0000-0001-7563-5324>

References for appendix

- [1] Salomaa V, Ketonen M, Koukkunen H, et al. Decline in out-of-hospital coronary heart disease deaths has contributed the main part to the overall decline in coronary heart disease mortality rates among persons 35 to 64 years of age in Finland: the FINAMI study. *Circulation*. 2003;108(6):691–696.
- [2] Salomaa V, Ketonen M, Koukkunen H, et al. Trends in coronary events in Finland during 1983–1997. The FINAMI study. *Eur Heart J*. 2003;24(4):311–319.
- [3] Pajunen P, Koukkunen H, Ketonen M, et al. The validity of the Finnish hospital discharge register and causes of death register data on coronary heart disease. *Eur J Cardiovasc Prev Rehabil*. 2005;12(2):132–137.